HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Arrail Group - The Outlook May Not Be Optimistic

Suzhou Zelgen Biopharmaceuticals (688266.CH) - Uncertainty Leads to Inaccurate Prediction on Outlook

China Healthcare Weekly (Mar.4)-Innovative Drug Cyclical Nature, Pet Vaccine Mkt, Legend Bio, Junshi

Industry Report - Insights on China IVD Industry

Kingmed Diagnostics (603882 CH) Vs Dian Diagnostics (300244 CH) - Which One Is Better?

Pre-IPO 3D Medicines - Insights on the Core Product, the Pipeline and the Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

ADICON Holdings Limited / Equity Capital Markets

<p>After more than 20 years of development in China, independent clinical laboratory (ICL) has achieved rapid growth, especially during the COVID-19. After <a href="https://www.smartkarma.com/entities/guangzhou-kingmed-diagnostics" target="_blank" data-smartkarma-citation="entities:30257:1" rel="noopener">Guangzhou Kingmed Diagnostics (603882 CH)</a> and <a href="https://www.smartkarma.com/entities/zhejiang-dian-diagnostics-a" target="_blank" data-smartkarma-citation="entities:19115:1" rel="noopener">Zhejiang Dian Diagnostics A (300244 CH) </a>got listed, the third-ranking ICL service provider in China, <a href="https://www.smartkarma.com/entities/adicon-holdings-limited" target="_blank" data-smartkarma-citation="entities:33786:1" rel="noopener">ADICON Holdings Limited (ADI HK)</a>, is also preparing to go public. On June 30, 2021, ADICON submitted its prospectus to the HKEX for listing on the main board. This insight mainly analyzed the industry characteristics, the business, and the concerns of the Company.</p>

After more than 20 years of development in China, independent clinical laboratory (ICL) has achieved rapid growth, especially during the COVID-19. After Guangzhou Kingmed Diagnostics (603882 CH) and Zhejiang Dian Diagnostics A (300244 CH) got listed, the third-ranking ICL service provider in China, ADICON Holdings Limited (ADI HK), is also preparing to go public. On June 30, 2021, ADICON submitted its prospectus to the HKEX for listing on the main board. This insight mainly analyzed the industry characteristics, the business, and the concerns of the Company.

Guangzhou Kingmed Diagnostics (603882 CH)

Pre-IPO ADICON Holdings Ltd - Insights on Industry, Business and Concerns